MOUNTAIN VIEW, Calif., Dec. 8, 2016 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it intends to offer newly issued shares of common stock, $0.01 par value (the "Offering" with such shares being the "Shares") pursuant to an underwritten public offering. The final terms of the Offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the Offering may be completed.
IRIDEX expects to use the net proceeds it will receive from this offering for working capital and other general corporate purposes. IRIDEX may also use a portion of the net proceeds for licensing or acquiring intellectual property or technologies to incorporate in its products, capital expenditures, to fund possible investments in and acquisitions of complementary businesses, partnerships, minority investments or to repay indebtedness.
Roth Capital Partners is acting as sole manager for the proposed Offering.
A shelf registration statement (File No. 333-213094) relating to the shares of common stock to be issued in the proposed offering was filed with the Securities and Exchange Commission (the "SEC") and was declared effective on August 26, 2016. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the preliminary prospectus supplement and accompanying prospectus will be filed with the Securities and Exchange Commission and, when available, may be obtained from Roth Capital Partners, LLC, 888 San Clemente, Newport Beach, CA 92660, (800) 678-9147 or email: rothecm@roth.com, by accessing the EDGAR database on the SEC's website at www.sec.gov, or by writing or calling IRIDEX at 1212 Terra Bella Avenue, Mountain View, CA 94043 or (650) 940-4700.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in this offering. There shall not be any sale of these securities in any state or jurisdiction in which such offering, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About IRIDEX
IRIDEX Corporation was founded in 1989 and is a leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. IRIDEX products are sold in the United States through both direct and independent sales forces and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries.
Logo - http://photos.prnewswire.com/prnh/20141001/149809
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/iridex-corporation-announces-proposed-public-offering-of-common-stock-300375656.html
SOURCE IRIDEX Corporation
Company Contact: Atabak Mokari, CFO & VP, Corporate Development, 650-940-4700, Investor Relations Contact: Matt Clawson, Pure Communications, 949-370-8500, matt@purecommunicationsinc.com
